

July 18th, 2025

Company name: RORZE CORPORATION

Listing: Tokyo Stock Exchange

Securities code: 6323

Representative: Yoshiyuki Fujishiro, Representative Director, President and Chief Executive Officer

Inquiries: Eiichi Isemura, General Manager of Administration Department

Telephone: +81-84-960-0001

(Corrections) Partial Corrections to the " FY2025 First Quarter (Ended May 31, 2025) Financial Briefing"

We would like to inform you of partial correction to the " FY2025 First Quarter (Ended May 31, 2025) Financial Briefing" we disclosed on July 11, 2025. After the disclosure, we found that the partial content contained errors. Necessary correction is shown as follows;


## Before correction

### Summary of Q1 FY2025

**RORZE**

- Quarterly Semi sales reached a record high, increasing equipment installation in Taiwan drove rapid sales growth
- Operating profit and ordinary profit declined with additional expenses by consolidating a subsidiary since last Q3
- US tariff policies have had no direct impact on the current business result

	FY'25 Q1	FY'24 Q1	YoY
Net sales	33,061	29,288	112.9%
Semi	28,230	26,836	105.2%
Analysis device ※	660	421	156.5%
FPD	1,001	262	382.3%
Life science	110	152	72.3%
Service/Parts etc. ※	3,058	1,615	189.3%
Operating profit	8,441	8,748	96.5%
Ordinary profit	7,241	11,361	63.7%
Profit attributable to owners of parent	5,263	8,774	60.0%
Average rate for the period (JPY/USD)	152	147	—



※ Part of the sales previously classified as "Service/Parts etc." becomes included in "Analysis device" in FY'25, and the figures for FY'24 have been revised accordingly.

On the page 5, The portion of the end user and equipment manufacturer in the graph "Quarterly Sales Trends" is corrected as


## After correction

### Summary of Q1 FY2025

**RORZE**

- Quarterly Semi sales reached a record high, increasing equipment installation in Taiwan drove rapid sales growth
- Operating profit and ordinary profit declined with additional expenses by consolidating a subsidiary since last Q3
- US tariff policies have had no direct impact on the current business result

	FY'25 Q1	FY'24 Q1	YoY
Net sales	33,061	29,288	112.9%
Semi	28,230	26,836	105.2%
Analysis device ※	660	421	156.5%
FPD	1,001	262	382.3%
Life science	110	152	72.3%
Service/Parts etc. ※	3,058	1,615	189.3%
Operating profit	8,441	8,748	96.5%
Ordinary profit	7,241	11,361	63.7%
Profit attributable to owners of parent	5,263	8,774	60.0%
Average rate for the period (JPY/USD)	152	147	—



※ Part of the sales previously classified as "Service/Parts etc." becomes included in "Analysis device" in FY'25, and the figures for FY'24 have been revised accordingly.